MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 27 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Cautionary tails
Joseph C. Del Paggio, Ian F. Tannock
2020· article· en· Annals of Oncology· Mathematics
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
1781P Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS
Alicia K. Morgans, Christopher J. Sweeney, Christopher J.D. Wallis, Susan Halabi, Andrew J. Armstrong, Ateesha F. Mohamed +4 more
2023· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
Richard S. Finn, Karen A. Gelmon, Johannes Ettl, Jamil Asselah, Aurelio Castrellon, A. Simon +6 more
2017· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry
Edoardo Francini, Steven Yip, Neesar Ahmed, H. Li, Luke Ardolino, Carolyn Evan +8 more
2017· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
fundno affno abstractunlabeled
LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
David S. Goldstein, Katrin Marie Sjoquist, Daniela Morales Espinosa, Sun Young Rha, Thorsten Oliver Goetze, Niall C. Tebbutt +14 more
2025· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Shigehira Saji, Antonio Llombart‐Cussac, Fabrice André, Mark E. Robson, Nadia Harbeck, Peter Schmid +8 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About